Shares in pharmaceutical company GlaxoSmithKline (GSK) surged more than 6% after the company revealed it had reached a settlement of up to $2.2bn (€2.01bn) to end tens of thousands of lawsuits in the ...

GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...

The pharmaceutical giant has settled the vast majority of cases around its drug Zantac in the US, boosting investor confidence in the company.

Citi analyst Peter Verdult maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £19.00. The ...

The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn ...

In fact, the company shares have seen a cumulative rise of 5.39 per cent or GBP 78.50. On Thursday, the green streak ...

Shares in British pharmaceutical giant GSK rose after the company said it resolved a vast majority of lawsuits in the U.S. claiming its discontinued heartburn medicine Zantac caused cancer. Shares ...

The UK FTSE 100 index increased by 0.3%, driven by significant gains in GSK following a settlement in the U.S. The market ...

The FTSE 100 index traded up 25.77 points, 0.3%, at 8,269.51. The FTSE 250 slipped 12.69 points, 0.1%, at 20,809.69, and the AIM All-Share down just 0.19 of a point at 736.47.

Among single stocks, GSK jumped about 6% after the British drugmaker agreed to pay up to $2.2 billion to settle U.S. lawsuits ...

European stocks rose on Thursday as investors awaited key US inflation data, with the healthcare sector leading gains after ...